Compositions and Methods for Treating Inflammation
AssigneeThe John Hopkins University
InventorsLieping Chen, Koji Tamada
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions to treat inflammation (LIGHT pathway) related disorders, and specifically liver inflammation or hepatitis. The invention also relates to methods treating LIGHT pathway related disorders. The invention further relates to kits for treating LIGHT pathway related disorders in a subject. The invention further relates to methods of identifying novel treatments for treating LIGHT pathway related disorders in a subject.
Claims21
A method of modulating an interaction between LIGHT and LTβR comprising, administering a LIGHT pathway protein modulator.
A method of modulating inflammation in a mammal, comprising modulating the LIGHT pathway protein signaling wherein disrupting an interaction between LIGHT and LTβR modulates inflammation of the a cell.
A method for the treatment and/or prophylaxis of a condition characterized by aberrant or otherwise unwanted inflammation in a subject, comprising modulating the LIGHT pathway protein signaling wherein disrupting an interaction between LIGHT and LTβR modulates inflammation of the a cell.
7-13. (canceled)
A pharmaceutical composition comprising a pharmaceutically effective amount of a LIGHT pathway modulator effective to treat, prevent, ameliorate, reduce or alleviate a LIGHT pathway related disorder or symptoms thereof and a pharmaceutically acceptable excipient.
(canceled)
A method to treat, prevent, ameliorate, reduce or alleviate a LIGHT pathway related disorder or symptoms thereof, comprising:
- administering to a subject in need thereof a composition comprising a pharmaceutically effective amount of a LIGHT pathway modulator.
19-28. (canceled)
A method for identifying lead compounds for a pharmacological agent useful in the treatment of a LIGHT pathway related disorder comprising:
- contacting a cell stimulated with concanavalin A with a test compound, and
- measuring LIGHT pathway activation or inflammation.
30-32. (canceled)
A kit comprising:
- a) a LIGHT pathway modulator and a pharmaceutically acceptable carrier and b) instructions for use.
A transgenic non-human animal comprising (i) a Y173F LIGHT protein or a fragment or variant thereof or (ii) a LIGHTΔL protein or a fragment or variant thereof.
35-42. (canceled)
A method of treating inflammation in a mammal, comprising:
- (a) identifying a mammal with, or at risk of developing, inflammation, wherein the cells of the cancer are identified as expressing soluble LIGHT;
- and (b) administering to the subject a compound comprising an agent that interferes with an interaction between LIGHT and a LTβR.
A method of diagnosing inflammation comprising, detecting the presence of soluble LIGHT in a sample from a subject.
45-49. (canceled)
Dependencies are inferred from the claim text.